CAS Number: 943319-70-8
Chemical Formula: C₂₉H₂₇F₃N₆O
Forme galénique: Comprimés pelliculés dosés à 15 mg, 30 mg et 45 mg
IUPAC Name: 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
EC Number: 851-222-7
Molecular Weight: 532.6
Indication thérapeutique: Traitement de la leucémie (ponatinib générique)
Content Uniformity: Contrôlé pour garantir une uniformité de teneur constante entre les dosages de 15 mg, 30 mg et 45 mg

Autres informations

Description supplémentaire:

Ponatinib FC tablets, available in 15 mg, 30 mg and 45 mg strengths, treat leukemia. The pivotal bioequivalence study has passed, with the dossier expected in Q1 2026 and a DCP slot requested for May 2026. Coripharma's generic version is being developed at its R&D facility in Iceland, powered entirely by sustainable energy, with its business development team available to discuss opportunities.